Drugs that contain Bendamustine Hydrochloride

1. List of Belrapzo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BELRAPZO before it's patent expiration?
More Information on Dosage

2. List of Bendeka drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(8 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(10 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(10 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Market Authorisation Date: 07 December, 2015

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BENDEKA before it's patent expiration?
More Information on Dosage

3. List of Treanda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445524 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8609863 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8895756 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8791270

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(3 years from now)

US8609863

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(3 years from now)

US8895756

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(3 years from now)

US8669279 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

US8883836 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

US9533955 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

US8344006 CEPHALON Liquid formulations of bendamustine
Sep, 2029

(6 years from now)

US8883836

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(6 years from now)

US8445524

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(6 years from now)

US8669279

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(6 years from now)

US8344006

(Pediatric)

CEPHALON Liquid formulations of bendamustine
Mar, 2030

(7 years from now)

US8436190 CEPHALON Bendamustine pharmaceutical compositions
Oct, 2030

(7 years from now)

US8436190

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Market Authorisation Date: 20 March, 2008

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl); For use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll)

Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)

How can I launch a generic of TREANDA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic